A practical reference on thymosin beta-4: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2025-08-14. Anything still debated is marked as such rather than presented as settled.
Interest in the fragment grew during the 1990s and 2000s, when it moved from laboratory work into sports and supplement markets. Anti-doping bodies added thymosin beta-4 fragments to prohibited lists, and a small number of adverse analytical findings have been reported in competition testing. Published controlled human trials remain scarce. Most mechanistic evidence comes from cell culture and animal models, and those studies examine endpoints such as cell migration, wound closure and inflammation markers. That evidence supports research interest but does not establish clinical benefit, and broad regenerative claims should be read as unverified.
TB-500 is a short synthetic peptide sold under a trade name rather than a systematic chemical name. Suppliers usually describe it as a fragment of thymosin beta-4 and ship it as a lyophilised powder intended for laboratory use. Because the label is commercial, the exact sequence attributed to it is not fully consistent across catalogues, and some listings present a seven-residue peptide while others describe related fragments of similar length. It is not an approved medicine in any major jurisdiction, and it is handled as a research chemical.
Thymosin beta-4 itself is a natural peptide of 43 residues found in many cell types and body fluids. Its best-characterised function is binding and sequestering actin monomers, which influences cytoskeletal dynamics. The sequence most often associated with TB-500, LKKTETQ, corresponds to part of that actin-binding region. A different fragment, Ac-SDKP, is also derived from the same parent peptide and is studied in its own right, which is one reason discussions of thymosin fragments can become confusing. The two are structurally distinct and are not interchangeable.
Discussion of the compound frequently appears alongside other short peptides described as fragments of larger proteins. That grouping is convenient but can be misleading, because fragment length, charge, and modification state determine how a peptide behaves in solution and in any experimental system. A seven-residue acetylated peptide and a full-length protein differ in mass by roughly an order of magnitude, and they cannot be assumed to share distribution or binding properties. Precision about which molecule is under discussion is the single most useful step when reading such material.
TB-500 is a shorthand label used in supplier catalogs and online discussion for a short synthetic peptide described as a fragment of thymosin beta-4. Most product listings present it as the N-terminally acetylated heptapeptide Ac-LKKTETQ, a sequence corresponding to the actin-binding region of the parent protein. The name is not a formal chemical designation and does not appear in standard nomenclature systems. Because labeling practices vary between vendors, two products sold under the same name may not contain the same molecule, and the stated sequence should be treated as a claim rather than a fixed definition.
| Property | Value | Notes |
|---|---|---|
| Name type | Commercial trade name | Not a systematic chemical identifier |
| Parent peptide | Thymosin beta-4 | 43-residue natural peptide |
| Common fragment sequence | LKKTETQ | Maps to part of the actin-binding region |
| Molecular size class | Roughly 0.8-1.0 kDa | Depends on exact fragment and terminal modification |
| Regulatory status | Prohibited in sport | Grouped with peptide hormones in many frameworks |
Research peptides are typically supplied as a white to off-white lyophilised powder in a sealed vial. The dry solid is more stable than a solution and is normally kept refrigerated or frozen until use. Dissolution is usually done in water, phosphate-buffered saline or a similar aqueous medium, depending on the assay. Because the material is hygroscopic and easily contaminated, opening vials in a low-humidity environment and recording the lot number before use are standard laboratory practices.
Once in solution, short peptides are generally less stable than the dry powder, and repeated freeze-thaw cycles are a common cause of loss. Laboratory guidance usually calls for aliquoting on first dissolution and storing aliquots at -20 °C or below, away from light. Adsorption to plastic and glass surfaces can lower measured concentration, particularly at low concentrations, so container material and buffer choice can affect results. Visible cloudiness, colour change or unexpected precipitate is a signal to re-check the material.
The fragment most often associated with the name carries the sequence Ac-LKKTETQ, matching residues 17 through 23 of thymosin beta-4. That region holds the actin-binding motif responsible for much of the parent protein's biochemical activity. Apart from N-terminal acetylation the peptide is unmodified and contains no disulfide bonds, so it shows little ordered secondary structure in solution. Full-length thymosin beta-4 is instead a 43-residue polypeptide of roughly 4.9 kDa found widely across mammalian cell types.
Material sold under this label typically arrives as a freeze-dried powder in a sealed vial with a certificate of analysis. Such certificates usually report reversed-phase chromatography purity plus a mass confirmation, and stated purities commonly sit between 95 and 99 percent. Counter-ion identity, residual trifluoroacetate, water content, and peptide net weight are separate specifications that a certificate may or may not include. A purity figure alone does not establish sequence identity, so independent mass verification remains the practical check.
The designation TB-500 circulates in laboratory and catalog contexts without a single agreed definition. Most product listings apply it to an N-terminally acetylated seven-residue fragment of thymosin beta-4, while other listings attach the same label to the full 43-residue protein. Because the term is commercial rather than systematic, two entries bearing identical names may describe different molecules. Any documentation should therefore state which sequence a given sample is claimed to contain.
The negotiation of the Statute of Autonomy of Catalonia, which obtained a similar level of self-government ─ although the system of agreements would not be implemented there ─ and similar institutions of its own, also culminated successfully. It was submitted to referendum on the same day as that of the Basque Country, being approved with an electoral participation similar to the Basque one. Shortly thereafter, the first elections to the respective parliaments would be held, which gave victory to the PNV nationalists in the Basque Country (with Carlos Garaikoetxea as the new lehendakari) and to the Convergència nationalists in Catalonia (with Jordi Pujol as the new President of the Generalitat de Catalunya). The approval of the Basque and Catalan Statutes ─ and the discussion of the galician one ─ triggered the autonomic expectations of many regions so that the government, faced with the prospect of triggering a "carousel" of autonomic referendums, decided to "rationalize" the process. The problem arose in Andalusia, where the first steps established by article 151 had already been taken to provide itself with a Statute with the same level of self-government as the Basque and Catalan ones, so the government was forced to call the autonomic referendum recommending at the same time the abstention of the voters. The referendum was held on February 28, 1980, and the result was that the autonomic initiative was approved by the absolute majority of the registered voters, which meant a disaster for the government and for the UCD.
== History == The history of light therapy can be traced back to ancient Egypt and India, where therapy with natural sunlight was first used to treat leucoderma. In the 1850s, Florence Nightingale's advocacy of exposure to clean air and sunlight for health restoration also contributed to the initial development of light therapy for treatments. Later, Downes and Blunt's experiment in 1877 suggested sunlight's effect on fungal growth inhibition, which further evidenced the efficiency of light therapy . The modern use of light therapy with artificial lights started in the late 19th century. The Danish Nobel Prize winner in medicine and physiology, Niels Finsen, pioneered the use of light as a therapy for skin tuberculosis (lupus vulgaris). His creation of the light device "Finsen lamp" as a lupus vulgaris treatment marked the beginning of modern light therapy. The application of LED lights in cosmetology became more popular in the 1980s, particularly for acne recovery, due to its ability of collagen production. Since the early 2000s, the use of LED light therapy in the medical field has become more versatile, including treatment for skin conditions, chronic diseases, and the realignment of human circadian rhythm. It has now become a commonly used therapy in both the beauty and medical fields.
This will allow healthcare professionals to digitally track the immunization status of beneficiaries (mother and children) on a real-time basis and address the vaccination needs immediately. Doctors and medical professionals may soon be able to manage appointments and maintain patient records over the vaccine platform CoWIN, with the National Health Authority (NHA) integrating it with the Ayushman Bharat Digital Health Mission (ABDM)—the backbone of India's digital healthcare system. This lightweight health management information system (HMIS) solution will allow small clinics and providers to manage appointments, patient information and prescriptions. The HMIS will be integrated with all ABDM modules and allow the doctor and clinic to create a health professional ID and a health facility ID.
Executive Order 13993 of January 20, 2021 (Revision of Civil Immigration Enforcement Policies and Priorities); Executive Order 14010 of February 2, 2021 (Creating a Comprehensive Regional Framework To Address the Causes of Migration, To Manage Migration Throughout North and Central America, and To Provide Safe and Orderly Processing of Asylum Seekers at the United States Border); Executive Order 14011 of February 2, 2021 (Establishment of Interagency Task Force on the Reunification of Families); Executive Order 14012 of February 2, 2021 (Restoring Faith in Our Legal Immigration Systems and Strengthening Integration and Inclusion Efforts for New Americans); Executive Order 14013 of February 4, 2021 (Rebuilding and Enhancing Programs To Resettle Refugees and Planning for the Impact of Climate Change on Migration). The orders ended efforts to reunite families and address mass migration from the source. Moreover, it decreased border security efforts.
Sources: en.wikipedia.org
== R == Ramberg–Bäcklund reaction Raney nickel Rap–Stoermer condensation Raschig phenol process Rauhut–Currier reaction Racemization Reductive amination Reductive dehalogenation of halo ketones Reed reaction Reformatsky reaction (also transliterated as Reformatskii reaction) Reilly–Hickinbottom rearrangement Reimer–Tiemann reaction Reissert indole synthesis Reissert reaction, Reissert compound Reppe synthesis Retropinacol rearrangement Rieche formylation Riemschneider thiocarbamate synthesis Riley oxidations Ring closing metathesis Ring opening metathesis Ritter reaction Robinson annulation Robinson–Gabriel synthesis Robinson Schopf reaction Rosenmund reaction Rosenmund reduction Rosenmund–von Braun synthesis Roskamp reaction Rothemund reaction Rupe rearrangement Rubottom oxidation Ruff–Fenton degradation Ruzicka large-ring synthesis
== Advantages == Many protein-containing solutions have the highest absorption at 280 nm in the spectrophotometer, the UV range. This requires spectrophotometers capable of measuring in the UV range, which many cannot. Additionally, the absorption maxima at 280 nm requires that proteins contain aromatic amino acids such as tyrosine (Y), phenylalanine (F) and/or tryptophan (W). Not all proteins contain these amino acids, a fact which will skew the concentration measurements. If nucleic acids are present in the sample, they would also absorb light at 280 nm, skewing the results further. By using the Bradford protein assay, one can avoid all of these complications by simply mixing the protein samples with the Coomassie brilliant blue G-250 dye (Bradford reagent) and measuring their absorbances at 595 nm, which is in the visible range and may be accurately measured by the use of a mobile smartphone camera. The procedure for Bradford protein assay is very easy and simple to follow. It is done in one step where the Bradford reagent is added to a test tube along with the sample. After mixing well, the mixture almost immediately changes to a blue color. When the dye binds to the proteins through a process that takes about 2 minutes, a change in the absorption maximum of the dye from 465 nm to 595 nm in acidic solutions occurs.
Post-infectious glomerulonephritis can occur after essentially any infection, but classically occurs after infection with the bacteria Streptococcus pyogenes. It typically occurs 1–4 weeks after a pharyngeal infection with this bacterium, and is likely to present with malaise, a slight fever, nausea and a mild nephritic syndrome of moderately increased blood pressure, gross haematuria, and smoky-brown urine. Circulating immune complexes that deposit in the glomeruli may lead to an inflammatory reaction. Diagnosis may be made on clinical findings or through antistreptolysin O antibodies found in the blood. A biopsy is seldom done, and the disease is likely to self-resolve in children in 1–4 weeks, with a poorer prognosis if adults are affected or if the affected children are obese.
Sources: en.wikipedia.org
A newer model of this type called UDM provides empirical profiles that can be imported into IQ-Q-TREE, Phylobayes, and RevBayes. A UDM can have thousands of profiles. Posterior mean site frequency (PMSF, 2018) is a computationally-cheaper approximation of the empirical-profile mixture models.
Endotoxins are negatively charged, and will bind to an anion exchanger. If the target substance is not also negatively charged, it will pass through the column before the endotoxin, and an effective separation can be achieved. This method is sometimes used in the purification of albumins (details follow). Ligands of known affinity to endotoxins can be coupled to an anion exchange system to increase its endotoxin binding strength and further improve the purity of the final product. Typical examples of endotoxin binding ligands include histamine, nitrogen-containing heterocyclic compounds, and polymyxin B. However, polymyxin B is known to induce production of interleukin-1, an exogenous pyrogen, and thus must be shown to be absent in the final product if used. Example of using anion exchange chromatography to purify albumin: 2% of the endotoxin does not bind to the column. However, this 2% washes out before the albumin peak, and can thus be removed simply by starting collection after this 2% has washed out. 10% of the endotoxin that does bind to the column (9.8% of the original total) will eventually wash out after the albumin peak. This can be prevented from entering the final product by stopping collection before this happens. The remaining 90% of the bound endotoxin (88.2% of the original total) must be cleaned off the column using NaOH An alternative to anion exchange is cation exchange chromatography, in which positively charged solutes bind to the solid chromatographic media. In this method, the target binds to the column instead of the endotoxin.
==== Cyclooxygenases ==== Prostaglandins are produced following the sequential oxygenation of arachidonic acid, DGLA or EPA by cyclooxygenases (COX-1 and COX-2) and terminal prostaglandin syntheses. The classic dogma is as follows:
== Further reading == Müller, Rainer H.; Mäder, Karsten; Gohla, Sven (3 July 2000). "Solid lipid nanoparticles (SLN) for controlled drug delivery – a review of the state of the art". European Journal of Pharmaceutics and Biopharmaceutics. 50 (1): 161–177. doi:10.1016/S0939-6411(00)00087-4. PMID 10840199. Shah, Mansi K.; Madan, Parshotam; Lin, Senshang (June 2014). "Preparation, in vitro evaluation and statistical optimization of carvedilol-loaded solid lipid nanoparticles for lymphatic absorption via oral administration". Pharmaceutical Development and Technology. 19 (4): 475–485. doi:10.3109/10837450.2013.795169. PMID 23697916. S2CID 42174732. Shah, Mansi K.; Madan, Parshotam; Lin, Senshang (3 October 2015). "Elucidation of intestinal absorption mechanism of carvedilol-loaded solid lipid nanoparticles using Caco-2 cell line as an in-vitro model". Pharmaceutical Development and Technology. 20 (7): 877–885. doi:10.3109/10837450.2014.938857. PMID 25069593. S2CID 40506806.
Sources: en.wikipedia.org
No. Thymosin beta-4 is a 43-residue natural peptide, while TB-500 is a commercial label applied to a short synthetic fragment of it. The two differ in length, sequence coverage and how they are handled in the laboratory.
Published work usually examines actin binding, cell migration and tissue repair endpoints in cell and animal models. Findings are generally described as preliminary, and controlled human data remain limited.
Because TB-500 is a trade name rather than a chemical identifier, different vendors and papers may attach it to different fragment lengths. Checking the stated sequence is the practical way to resolve the ambiguity.
Most listings describe it as a short acetylated peptide with the sequence Ac-LKKTETQ, presented as a region of thymosin beta-4. The label is a trade-style name rather than a standardized chemical name, so the exact content of a given vial depends on the supplier.